Fluidigm Corp (FLDM): Levin Capital Strategies Reports 25.2% Stake

Page 13 of 20

Page 13 of 20 – SEC Filing
A.  LCS
(a)            As of the close of business on October 14, 2016, LCS beneficially owned 7,317,390 Shares.
Percentage:  Approximately 25.2%.
(b)           1. Sole power to vote or direct vote:  0
2. Shared power to vote or direct vote:  5,478,118*
3. Sole power to dispose or direct the disposition:  0
4. Shared power to dispose or direct the disposition: 7,317,390*
* See Item 5(d) for further discussion.
(c)           The transactions in the Shares by LCS during the past 60 days are set forth in Schedule A and are incorporated herein by reference.
B.  LCS GP
(a)            As the General Partner of LCS, LCS GP is deemed to beneficially own the 7,317,390 Shares beneficially owned by LCS.
Percentage:  Approximately 25.2%.
(b)           1. Sole power to vote or direct vote:  0
2. Shared power to vote or direct vote:  5,478,118*
3. Sole power to dispose or direct the disposition:  0
4. Shared power to dispose or direct the disposition: 7,317,390*
* See Item 5(d) for further discussion.
(c)           LCS GP has not undertaken any transactions in the Shares during the past 60 days.   The transactions in the Shares by LCS during the past 60 days are set forth in Schedule A and are incorporated herein by reference.
C.  Trilogy
(a)            As of the close of business on October 14, 2016, Trilogy beneficially owned 51,068 Shares.
Percentage:  Less than 1.0%.
(b)           1. Sole power to vote or direct vote:  0
2. Shared power to vote or direct vote:  51,068 *
3. Sole power to dispose or direct the disposition:  0
4. Shared power to dispose or direct the disposition: 51,068 *
* As the general partner to Trilogy, LCSL has shared voting and dispositive power over these Shares.  As the investment advisor to Trilogy, LCS has shared voting and dispositive power over these Shares.
(c)           The transactions in the Shares by Trilogy during the past 60 days are set forth in Schedule A and are incorporated herein by reference.

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 13 of 20